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Imatinib (also known as STI571 or Gleevec) is one of the
great success stories of cancer therapy and is a milestone in
small-molecule drug discovery and molecular targeted
therapies. Imatinib is the current first-line therapy for all
stages of chronic myelogenous leukemia (CML), in which the
chronic phase of the disease is characterized by the increased
proliferation of the myeloid lineage and which is
cytogenetically diagnosed by the presence of the Philadelphia
chromosome. This contains a fusion gene encoding the
oncoprotein BCR-ABL, in which a part of the BCR protein is
fused to the non-receptor ABL tyrosine kinase, causing it to
become constitutively active. The deregulated kinase activity
of BCR-ABL accounts for the oncogenicity of the protein and
is inhibited by imatinib. Since the approval of imatinib by
the US Food and Drug Administration in May 2001, there has
been a dramatic reduction in the number of bone marrow
transplants for CML in the US; imatinib monotherapy has
also been used successfully to induce a complete cytogenetic
response in about 75-90% of newly diagnosed CML patients,
although drug resistance is a problem with advanced stages of
CML [1].
P Pr ro ot te ei in n   t ta ar rg ge et ts s   o of f   i im ma at ti in ni ib b
Imatinib is not entirely specific and targets tyrosine kinases
other than ABL, notably the receptor tyrosine kinases KIT
and PDGFR (platelet-derived growth factor receptor). This
lack of specificity has been exploited in the clinic, and
imatinib has also been approved for the treatment of
chronic eosinophilic leukemia (CEL), which is caused by a
FIP1L1-PDGFRα fusion, and for gastrointestinal stromal
tumors (GISTs), caused by mutations of KIT or PDGFRα
(reviewed in [1]). There has been increasing interest in
understanding other potential targets of imatinib to
evaluate the specificity, safety and potential off-target effects
of this first-in-class drug.
The traditional approach to identifying imatinib targets is
through in vitro assays with a panel of recombinant kinases
to measure inhibitor binding. This approach is limited by
the pre-selection of test targets and tends to provide poor
indicators for drug activity in vivo. Two recent studies
circumvent this problem by using cell extracts from the
CML cell line K562 to identify binding targets of imatinib
[2,3]. In the first [2], imatinib was modified to allow
attachment to solid support and incubated with cell
lysates, and the bound proteins were identified by tandem
mass spectrometry. The second approach [3] used seven
broad-specificity kinase inhibitors attached to beads.
These mixed kinase inhibitor beads (kinobeads) were
incubated with cell lysates and bound proteins were again
identified by tandem mass spectrometry. To identify
A Ab bs st tr ra ac ct t
The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in
treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a
1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights
into the binding specificity and the off-target effects of the inhibitor.
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imatinib before binding to the kinobeads. Proteins that no
longer bound to the kinobeads, because their binding sites
were occupied by imatinib, were identified by comparative
analysis [3]. 
Both approaches have confirmed the selective nature of
imatinib: no more than five proteins from K562 cell lysates
bound imatinib as compared with about 30 proteins for
another BCR-ABL inhibitor, dasatinib. The explanation for
this difference is that dasatinib targets the active kinase
conformation, which is highly conserved and thus shared
by other kinases, whereas imatinib targets the inactive
conformation, which is unique to the ABL kinase [4].
Surprisingly, both approaches also identified the first non-
tyrosine kinase target of imatinib, NQO2. Others may
follow: indeed, a recent screen in yeast identified the
vacuolar ATPase (V-ATPase), an evolutionarily conserved
proton pump, as a target of imatinib [5], and imatinib may
interact with other non-kinase targets that could have
eluded detection by the K562 cell-based experiments.
Structural studies, including one just published by Kuriyan
and colleagues in BMC Structural Biology [6], show that this
promiscuity reflects the flexibility of the inhibitor, a
consideration that is likely to apply broadly to small-
molecule inhibitors.
F Fl le ex xi ib bi il li it ty y   o of f   i im ma at ti in ni ib b   i in n   b bi in nd di in ng g   t to o   t ta ar rg ge et ts s   
The Kuriyan group has analyzed the crystal structure at
1.75 Å of a dimer of human NQO2 bound to imatinib
[6]. The objective of the structural study was to cast light
on possible side-effects attributable to imatinib binding
to NQO2, and a spectrophotometric assay confirmed
binding of imatinib to NQO2 with a concentration for
50% inhibition (IC50) of 82 nM, consistent with earlier
reports [2,3] and well within the physiological range of
the concentration of imatinib found in the serum of
patients (about 1 µM; referenced in [6]). NQO2 is a
cytoplasmic flavoprotein that is involved in the cellular
response to oxidative stress, although its mechanism of
action is not well understood. NQO2 is highly expressed
in myeloid cells, and knockdown by RNA interference in
K562 cells results in reduced proliferation (referenced in
[6]). However, NQO2 knockout mice show myeloid
hyperplasia and increased sensitivity to chemical
carcinogenesis (referenced in [6]). The potential clinical
side-effect(s) of inhibition of NQO2, despite the
elucidation of the exact mechanism of imatinib
inhibition, are thus not yet clear. The structure does show,
however, that the structural flexibility that allows
imatinib to bind to NQO2 is also the basis for its binding
to other, more clinically relevant targets.
Imatinib interacts with NQO2 primarily through
hydrophobic interactions, making no direct hydrogen
bonds (Figure 1a). Steric constraints lead imatinib to adopt
a compacted horseshoe shape that partially extends into the
solvent, and the isoalloxazine ring of the NQO2 flavin
cofactor in the active site stacks with the pyridine and
pyrimidine rings of imatinib. The related kinase inhibitor
dasatinib cannot make this stacking interaction, and this
explains why it does not bind to NQO2 [6]. The structure
also demonstrates why imatinib cannot bind the closely
related NQO1, which has 49% identity and a similar
structure to NQO2: steric hindrance from Phe232, Tyr128
and Pro68 are likely to occlude the imatinib binding site
[6].
Comparison of the NQO2-imatinib structure with that of
imatinib bound to ABL (Figure 1a,b) reveals the flexibility
of imatinib binding and demonstrates the difficulty in
designing a drug that has no off-targets. In the ABL-imatinib
complexes (reviewed in [4]), the DFG motif (Asp381-
Phe382-Gly383) that characterizes the activation loop of
the kinase is rotated by 180° and adopts a flipped-out
conformation (Figure 1b). This DFG-out conformation
creates a binding pocket for imatinib, which on binding
causes the activation loop to fold towards the active site and
at the same time induces contraction of the phosphate-
binding P-loop, which also binds to imatinib [4]. Overall,
imatinib uses six hydrogen bonds and several van der Waals
interactions to stabilize the complex. In the imatinib-ABL
complex, imatinib adopts an extended conformation that is
seen in several other kinase-imatinib structures [4] and that
differs significantly from the compact, ring-stacking
conformation seen in the NQO2 structure [6]. 
The structures of imatinib bound to the SYK kinase, or to
the desmethyl imatinib analog bound to SRC kinase,
however, are similar to the conformation seen in NQO2,
which shows that this is a minor but not a unique
conformation for imatinib [6]. Future drug designs will
need to account for the distinct conformations that a small
molecule inhibitor can adopt if they are to understand the
full range of targets that a drug can bind.
C Cl li in ni ic ca al l   e ef ff fe ec ct ts s   o of f   i im ma at ti in ni ib b   
The multi-target specificity of imatinib has had many
clinical benefits. As mentioned earlier, imatinib has been
approved for the treatment of CML, CEL and GIST because
of its inhibition of the BCR-ABL, PDGFRα and KIT tyrosine
kinases (Figure 2). Recent clinical and preclinical studies
have expanded the use of imatinib for the treatment of
other diseases, including systemic mastocytosis, which also
involves the KIT and PDGFR tyrosine kinases, and (in
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probably acts in fibrotic disorders through effects on the
ABL tyrosine kinase, which has been implicated in TGFβ-
induced fibrotic responses, and through the PDGFR: both of
these are known to be involved in two major pro-fibrotic
pathways activated in systemic sclerosis [7]. 
In mouse models, there is evidence that imatinib may be
effective in the treatment of ischemic strokes [8] and in
several inflammatory and autoimmune diseases [9]. The
effects on inflammatory and autoimmune disease are
consistent with phase I clinical studies and case reports
detailing positive effects in rheumatoid arthritis, psoriasis,
spondyloarthritis and Crohn's disease (referenced in [9]). A
recent paper [9], again on a mouse model, reports that
imatinib may be effective for the treatment of type 1
diabetes, largely through inhibition of PDGFR. Given the
involvement of NQO2 in oxidative stress, it will be of
interest to determine whether the inhibition of this
oxidoreductase can contribute to the anti-inflammatory
activity of imatinib. 
Known mild adverse effects of imatinib include edema,
muscle cramps, diarrhea and bone-marrow toxicity, and
these do cause some patients to discontinue treatment
[1]. Their cause is currently unknown. Cardiotoxicity has
been reported as a potentially severe adverse effect of
imatinib (reviewed in [10]): in this case the adverse effect
seems to be due to inhibition of the primary target of
imatinib, the ABL kinase, but the extent to which the
cardiotoxicity results from imatinib treatment is
controversial [10].
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Atomic interactions of imatinib with ( (a a) ) NQO2 (Protein Data Bank (PDB) code 1FW3) and ( (b b) )   ABL kinase domain (PDB 1IEP). (a) A monomer of
NQO2 (green) is shown bound to its cofactor FAD (blue) and to imatinib (red). Imatinib uses stacking interactions with FAD and makes
hydrophobic contacts with both subunits in the NQO2 dimer. Only residues involved in hydrophobic interactions from a single monomer are
depicted. (b) The ABL kinase domain (cyan) is depicted with the DFG motif (yellow) and residues involved in direct hydrogen binding (blue) either
through side chains or the peptide backbone. D381 also makes a direct hydrogen-bonding contact with imatinib (red).
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The promiscuity of imatinib allows its application in multiple diseases.
The structure of imatinib (from PDB 1IEP) is shown in the middle, with
carbon (green), nitrogen (blue) and oxygen (red) atoms displayed.
Shaded boxes indicate imatinib targets; blue shading indicates targets
that are tyrosine kinases. CEL, chronic eosinophilic leukemia; CML,
chronic myelogenous leukemia; GIST, gastrointestinal stromal tumors;
KIT, receptor for stem cell factor; PDGFR, platelet-derived growth
factor receptor; sMC, systemic mastocytosis; SSc, systemic sclerosis;
V-ATPase, vacuolar ATPase. Imatinib has been shown to be a versatile drug with clinical
benefit for treating CML, GIST and CEL and has potential
for use in a variety of other diseases. Understanding how
imatinib and other small-molecule drugs interact with their
cellular targets is important for rational drug design and
prediction of potential off-target effects. The limited
promiscuity of imatinib may be optimal, allowing its use in
a variety of diseases with mild adverse effects. Imatinib has
revolutionized the treatment of CML and may be poised for
more clinical successes.
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